Oncology & Hematology
Accelerating market approvals for life-saving compounds: our formula for your success
TFS HealthScience provides oncology and hematology scientific, medical, regulatory, and operational expertise and tailored solutions to ensure the successful execution of complex oncology trials. This highly specialized discipline requires extreme attention to detail combined with a broad understanding of your requirements. Your trial is unique—we have the strategy and experts to support it from design to completion.
By engaging TFS oncology and hematology CRO services, you gain access to:
Global, international, and regional experience in oncology
Partnership-minded approach and customer-centric focus
Access to our global key opinion leaders and site network
In-depth therapeutic, scientific, and strategic knowledge
Operational delivery excellence through proactive planning, risk mitigation, and standardized processes
Commitment and executive oversight from TFS’ most senior personnel, including our oncology hematology leadership team
TFS has supported more than 300 clinical trials in oncology and hematology across all phases
About one-third of TFS studies are in the oncology & hematology area
We built our expertise through longstanding hands-on experience covering a broad range of indications across all phases of development.
Early Phase
Supporting your research and development strategically at its crucial go/no-go stage
Phases II – III
Taking your drug or product to approval
Late Phase
Getting the real-world data you need
Resources
Enhancing and integrating with your in-house or outsourced resources as and when needed
Consulting
Providing commercially and therapeutically relevant advice to support your decisions throughout clinical development
Experience you can trust
The TFS oncology and hematology team has specialists who understand the challenges of modern oncology and hematology trials. From complex early-phase trials, including basket trials, precision medicines, immuno-oncology, and rare hematologic diseases, we are here to support the development of your trial.
Our experience over the last five years includes indications such as NSCLC, breast cancer, prostate cancer, solid tumors, HPV/cervical cancer, and malignant hematology studies.
Nearly 800 sites
vetted and managed
More than 300
studies performed
Nearly 9,000 patients
participated
Case Study: First-in-Man Solid Tumor Oncology
TFS was selected to provide full CRO services including site identification, initiation, and training; patient enrollment, monitoring, data management, biostatistics, and programming; project management; medical writing, safety, medical monitoring, and regulatory consulting. This open study required close follow up on safety and disease progression.
Part One: (Dose Escalation): 3 sites
Part Two: (Dose Expansion): 6 sites
Study Phase: First-in-Man, I/IIb
Indication: Solid Tumors
Sites: 6
Oncology & Hematology Insights
One project, one team
TFS is committed to developing a solution-driven partnership that drives your success. Located across more than 20 countries, our depth and range of expertise can be put to use for your next global, regional, or local trial.
Kris O’Brien
VICE PRESIDENT, HEAD OF ONCOLOGY & RARE DISEASES
- Nearly 40 years of experience in oncology and rare diseases across all phases
- Demonstrated leadership leveraging trust, quality, and efficiency for pharmaceutical, biotech, and CROs
- Deep understanding of patient recruitment, retention, and study visit design
- Oversees a global team of experts ranging from physicians to clinical specialists
Right people, right solutions
If you are looking for a responsive mid-size CRO who understands oncology & hematology development, you are in the right place. We are the right people with the right solutions, and we have the expertise to support that claim. Work with us and let us demonstrate real collaboration—talk to us today.